Imatinib targets PDGF signaling in melanoma and host smooth muscle neighboring cells

Journal of Cellular Biochemistry

Volumn 111, Issue 2, 2010, Pages 433-441

  Pirraco, Ana ^a   Coelho, Pedro ^a   Rocha, Ana ^a   Costa, Raquel ^a   Vasques, Luísa ^a   Soares, Raquel ^a  

^a University of Porto   (Portugal)

Author keywords

Angiogenesis; Glivec; Melanoma; Smooth muscle cells

Indexed keywords

IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ANIMALS; MELANOMA, EXPERIMENTAL; MICE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PATHOLOGIC; PARACRINE COMMUNICATION; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 77957254371     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22725     Document Type: Article

References (39)

1. Abramsson A, Lindblom P, Betsholtz C. 2003. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112:1142-1151.
2. Andrae J, Gallini R, Betsholtz C. 2008. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22:1276-1312.
3. Armulik A, Abramsson A, Betsholtz C. 2005. Endothelial/pericyte interactions. Circ Res 97:512-523.
4. Barnhill RL, Xiao M, Graves D, Antoniades HN. 1996. Expression of plateletderived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo. Br J Dermatol 135:898-904.
5. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. 2003. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295.
6. Betsholtz C. 2004. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 15:215-228.
7. Boyle P, Dore JF, Autier P, Ringborg U. 2004. Cancer of the skin: A forgotten problem in Europe. Ann Oncol 15:5-6.
8. Costa C, Incio J, Soares R. 2007. Angiogenesis and chronic inflammation: Cause or consequence? Angiogenesis 10:149-166.
9. Folkman J. 2007. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286.
10. Frost EE, Zhou Z, Krasnesky K, Armstrong RC. 2009. Initiation of oligodendrocyte progenitor cell migration by a PDGF-A activated extracellular regulated kinase (ERK) signaling pathway. Neurochem Res 34:169-181.
11. Furuhashi M, Sjoblom T, Abramsson A, Ellingsen J, Micke P, Li H, Bergsten- Folestad E, Eriksson U, Heuchel R, Betsholtz C, Heldin CH, Ostman A. 2004. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res 64:2725-2733.
12. Giblin AV, Thomas JM. 2007. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg 60:32-40.
13. Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C. 2007. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 121:2606-2614.
14. Heldin CH, Westermark B. 1999. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316.
15. Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG. 2006. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). J Cutan Pathol 33:280-285.
16. Jain RK, Booth MF. 2003. What brings pericytes to tumor vessels? J Clin Invest 112:1134-1136.
17. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer statistics, 2008. CA Cancer J Clin 58:71-96.
18. Lassam N, Bickford S. 1992. Loss of c-kit expression in cultured melanoma cells. Oncogene 7:51-56.
19. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. 2000. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12:547-554.
20. Levi F. 2006. Chronotherapeutics: The relevance of timing in cancer therapy. Cancer Causes Control 17:611-621.
21. Levi F, Focan C, Karaboue A, de la Valette V, Focan-Henrard D, Baron B, Kreutz F, Giacchetti S. 2007. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 59:1015-1035.
22. Mayorga ME, Sanchis D, Perez de Santos AM, Velasco A, Dolcet X, Casanova JM, Baradad M, Egido R, Pallares J, Espurz N, Benitez D, Mila J, Malvehy J, Castel T, Comella JX, Matias-Guiu X, Vilella R, Marti RM. 2006. Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines. Melanoma Res 16:127-135.
23. McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, Bar-Eli M. 2004. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol 122:400-405.
24. Nakagawa H, Takiguchi T, Nakamura M, Furuyama A, Koyanagi S, Aramaki H, Higuchi S, Ohdo S. 2006. Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice. Biochem Pharmacol 72:1237-1245.
25. Ogawa Y, Kawamura T, Furuhashi M, Tsukamoto K, Shimada S. 2008. Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate. J Dermatol Sci 51:190-199.
26. Ohdo S, Koyanagi S, Suyama H, Higuchi S, Aramaki H. 2001. Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat Med 7:356-360.
27. Ostman A. 2004. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15:275-286.
28. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A. 2003a. PDGF receptors as cancer drug targets. Cancer Cell 3:439-443.
29. Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin CH, McSheehy P, Wartmann M, Ostman A. 2003b. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 9:3779-3787.
30. Redondo P, Lloret P, Andreu EJ, Inoges S. 2004. Imatinib mesylate in cutaneous melanoma. J Invest Dermatol 123:1208-1209.
31. Rocha A, Azevedo I, Soares R. 2007. Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells. Angiogenesis 10:279-286.
32. Roussidis AE, Mitropoulou TN, Theocharis AD, Kiamouris C, Papadopoulos S, Kletsas D, Karamanos NK. 2004. STI571 as a potent inhibitor of growth and invasiveness of human epithelial breast cancer cells. Anticancer Res 24:1445-1447.
33. Sennino B, Falcon BL, McCauley D, Le T McCauley T, Kurz JC, Haskell A, Epstein DM, McDonald DM. 2007. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 67:7358-7367.
34. Shen SS, Zhang PS, Eton O, Prieto VG. 2003. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 30:539-547.
35. Soares R, Guerreiro S, Botelho M. 2007. Elucidating progesterone effects in breast cancer: Cross talk with PDGF signaling pathway in smooth muscle cell. J Cell Biochem 100:174-183.
36. Soria A, Cario-Andre M, Lepreux S, Rezvani HR, Pasquet JM, Pain C, Schaeverbeke T, Mahon FX, Taieb A. 2008. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: A preclinical study. Dermatology 216:109-117.
37. Tallquist M, Kazlauskas A. 2004. PDGF signaling in cells and mice. Cytokine Growth Factor Rev 15:205-213.
38. Vlahovic G, Ponce AM, Rabbani Z, Salahuddin FK, Zgonjanin L, Spasojevic I, Vujaskovic Z, Dewhirst MW. 2007. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 97:735-740.
39. von Mehren M. 2005. Targeted therapy with imatinib: Hits and misses? J Clin Oncol 23:8-10.